Cinacalcet therapy and cardiovascular risk in hemodialysis patients

被引：0
|
作者：
Zelaznicka, Marzena
Kocelak, Piotr [1 ,2 ]
Glinianowicz, Magdalena Olszanecka [1 ,2 ]
Chudek, Jerzy [3 ]
机构：
[1] Slaskiego Uniwersytetu Med Katowicach, Zaklad Promocji Zdrowia, Katowice, Poland
[2] Slaskiego Uniwersytetu Med Katowicach, Leczenia Otylosci Katedry Patofizjol, Katowice, Poland
[3] Slaskiego Uniwersytetu Med Katowicach, Zaklad Patofizjol, Katedry Patofizjol, Katowice, Poland
来源：
POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ | 2012年 / 66卷
关键词：
end-stage kidney disease; cardiovascular risk; vascular calcification; secondary hyperparathyroidism; cinacalcet; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; GROWTH-FACTOR; 23; DOSE VITAMIN-D; VASCULAR CALCIFICATION; MINERAL METABOLISM; ALL-CAUSE; PARATHYROID-HORMONE; DIALYSIS PATIENTS; SERUM-LEVELS;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Patients with end-stage kidney disease are at high cardiovascular risk due to accelerated atherosclerosis development. Important factors that accelerate the development of atherosclerosis in this group are calcium-phosphorus disturbances causing vascular calcification. Therefore, slowing the development and progression of vascular calcification is a novel therapeutic target in the treatment of calcium and phosphorus disturbances associated with chronic kidney disease. It seems that cinacalcet, a calcimimetic of the second generation, used in patients with refractory secondary hyperparathyroidism can slow the progression of vascular calcification and potentially reduce the cardiovascular risk. This paper reviews the current literature on the pathogenesis of vascular calcification and the potential impact of cinacalcet to reduce cardiovascular risk in patients with end-stage kidney disease.
引用
收藏
页码：722 / 729
页数：8
相关论文
共 50 条
  • [1] Cinacalcet and cardiovascular mortality in hemodialysis patients
    Klein, Gordon L.
    [J]. KIDNEY INTERNATIONAL, 2010, 78 (08) : 820 - 820
  • [2] THE CARDIOVASCULAR EFFECTS OF CINACALCET IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM
    Choi, Bum Soon
    Choi, Sun Ryoung
    Park, Hoon Suk
    Hong, Yu Ah
    Chung, Byung Ha
    Kim, Young Soo
    Yang, Chul Woo
    Kim, Yong-Soo
    Park, Cheol Whee
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 442 - 442
  • [3] The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
    Parfrey, Patrick S.
    Drueeke, Tilman B.
    Block, Geoffrey A.
    Correa-Rotter, Ricardo
    Floege, Juergen
    Herzog, Charles A.
    London, Gerard M.
    Mahaffey, Kenneth W.
    Moe, Sharon M.
    Wheeler, David C.
    Kubo, Yumi
    Dehmel, Bastian
    Goodman, William G.
    Chertow, Glenn M.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 10 (05): : 791 - 799
  • [4] Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial
    Wheeler, David C.
    London, Gerard M.
    Parfrey, Patrick S.
    Block, Geoffrey A.
    Correa-Rotter, Ricardo
    Dehmel, Bastian
    Drueeke, Tilman B.
    Floege, Juergen
    Kubo, Yumi
    Mahaffey, Kenneth W.
    Goodman, William G.
    Moe, Sharon M.
    Trotman, Marie-Louise
    Abdalla, Safa
    Chertow, Glenn M.
    Herzog, Charles A.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2014, 3 (06):
  • [5] Cinacalcet Hydrochloride Therapy for Secondary Hyperparathyroidism in Hemodialysis Patients
    El-Shafey, Eid M.
    Alsahow, Ali E.
    Alsaran, Khalid
    Sabry, Alaa A.
    Atia, Mohamed
    [J]. THERAPEUTIC APHERESIS AND DIALYSIS, 2011, 15 (06) : 547 - 555
  • [6] Cinacalcet and gastrointestinal bleeding risk in patients receiving hemodialysis
    Liu, Jiannong
    Guo, Haifeng
    Lin, Tzu-Chieh
    Wetmore, James B.
    Bradbury, Brian D.
    Gilbertson, David T.
    Nieman, Kimberly
    Peng, Yi
    Sprafka, J. Michael
    Dluzniewski, Paul J.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 (02) : 141 - 148
  • [7] COMPARISON OF CINACALCET PLUS PARICALCITOL TO CINACALCET PLUS CALCITRIOL THERAPY IN HEMODIALYSIS PATIENTS WITH SEVERE HYPERPARATHYROIDISM
    Sezer, Siren
    Bal, Zeynep
    Tutal, Emre
    Kal, Oznur
    Yavuz, Demet
    Yildrim, Ibrahim
    Sayin, Burak
    Ozelsancak, Ruya
    Ozkurt, Sultan
    Turk, Suleyman
    Ozdemir, Nurhan
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 463 - 463
  • [8] Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
    Moe, Sharon M.
    Chertow, Glenn M.
    Parfrey, Patrick S.
    Kubo, Yumi
    Block, Geoffrey A.
    Correa-Rotter, Ricardo
    Drueeke, Tilman B.
    Herzog, Charles A.
    London, Gerard M.
    Mahaffey, Kenneth W.
    Wheeler, David C.
    Stolina, Maria
    Dehmel, Bastian
    Goodman, William G.
    Floege, Juergen
    [J]. CIRCULATION, 2015, 132 (01) : 27 - 39
  • [9] Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events Trial (vol 3, e001363, 2014)
    Wheeler, David C.
    London, Gerard M.
    Parfrey, Patrick S.
    Block, Geoffrey A.
    Correa-Rotter, Ricardo
    Dehmel, Bastian
    Drueeke, Tilman B.
    Floege, Juergen
    Kubo, Yumi
    Mahaffey, Kenneth W.
    Goodman, William G.
    Moe, Sharon M.
    Trotman, Marie-Louise
    Abdalla, Safa
    Chertow, Glenn M.
    Herzog, Charles A.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (01):
  • [10] Cardiovascular risk markers in hemodialysis patients
    Urso, S
    Garozzo, M
    Milone, F
    Battaglia, G
    [J]. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2004, 27 (12): : 1083 - 1090
12345